Álvarez MP, Hernández RG, Valdes EGD, Navarro RF, Casillas SC, Hernández SA

Language: Spanish
References: 12
Page: 113-116
PDF size: 192.07 Kb.

ABSTRACT

Introduction: non-conventional sedatives and those off-label, such as inhaled anesthetics, were used due to the shortage of medicines during the SARS-CoV-2 pandemic. Objectives: to compare the cost and results obtained with the use of inhaled anesthetics versus intravenous sedatives in COVID-19. Material and methods: retrospective study in a public reference hospital ICU. A calculation of sedation costs was made of the first two days of ICU stay. Drug doses were taken from the clinical records and acquisition costs directly from CompraNet. Mean costs per medication and per group are compared. Results: of 151 patients, 81 received intravenous sedation and 70 received inhaled anesthesia with or without intravenous sedatives. There was no difference in mortality, days of mechanical ventilation, ICU stay, and hospital stay between groups. A significant reduction in costs derived from the less use of midazolam, propofol and dexmedetomidine (p < 0.0001), and a difference between means of total sedation costs of $4,108.42 Mexican pesos per patient per day was observed with inhaled anesthesia. Conclusions: inhaled anesthesia during the COVID-19 pandemic compared to intravenous sedation allowed a cost reduction in the first two days of ICU stay.

REFERENCES

1. Ñamendys-Silva SA. Case fatality ratio of COVID-19 patients requiring invasive mechanical ventilation in Mexico: an analysis of nationwide data. Crit Care. 2021;25:68.

2. Pettus K, Cleary JF, de Lima L, Ahmed E, Radbruch L. Availability of internationally controlled essential medicines in the COVID-19 pandemic. J Pain Symptom Manage. 2020;60(2):e48-e51.

3. Carrillo-Esper, R, Velarde Pineda AA, Zepeda Mendoza AD, Arellano Ramírez A, Pérez Calatayud A, Mendoza Popoca CU, et al. Documento de posicionamiento: uso de sedación inhalada en el paciente críticamente enfermo. Med Crit. 2022;36(Suppl: 2):s43-s64.

4. Álvarez-Maldonado P, Cueto-Robledo G, Cerón-Díaz U, Pérez-Rosales A, Navarro-Reynoso F, Cicero-Sabido R. Indicadores de calidad en una unidad de cuidados intensivos respiratorios: Análisis inicial de la base de datos DEDUCIR. Med Intensiva. 2012; 36(7):518-520.

5. CompraNet – Secretaría de Hacienda y Crédito Público. [Consultado el 15 de marzo de 2022] Disponible en: https://compranet.hacienda.gob.mx/web/login.html

6. Banco Mundial. The economic impacts of the COVID-19 crisis. [Consultado el 2 de octubre de 2022] Available in: https://www.worldbank.org/en/publication/wdr2022/brief/chapter-1-introduction-the-economic-impacts-of-the-covid-19-crisis

7. Villagómez Ortíz A. Costo-efectividad de la Atención en Cuidados Intensivos. Rev Asoc Mex Med Crit Ter Int. 2012;4:192-193.

8. L'her E, Dy L, Pili R, Prat G, Tonnelier JM, Lefevre M, et al. Feasibility and potential cost/benefit of routine isoflurane sedation using an anesthetic-conserving device: a prospective observational study. Respir Care. 2008;53(10):1295-1303.

9. Bisbal M, Arnal JM, Passelac A, Sallée M, Demory D, Donati SY, et al. Efficacy, safety and cost of sedation with sevoflurane in intensive care unit. Ann Fr Anesth Reanim. 2011;30(4):335-341.

10. Pedersen CA, Schneider PJ, Ganio MC, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Impact of COVID-19 pandemic on pharmacy operations-2020. Am J Health Syst Pharm. 2021;78(18):1701-1712.

11. Landoni G, Belloni O, Russo G, Bonaccorso A, Cara G, Jabaudon M. Inhaled sedation for invasively ventilated COVID-19 patients: a systematic review. J Clin Med. 2022;11(9):2500.

12. Ramírez García HA, Cerda Arteaga JM, Chávez Pérez C, Sánchez Nava VM. Sedación con sistema AnaConDa en pacientes COVID-19 crítico y su impacto en días de ventilación mecánica. Med Crit. 2022;36:138-141.